寡进展性肾细胞癌:手术的角色是什么?
本文概述了肾细胞癌寡进展的生物学机制与模式,以及手术在該情境下的最新角色。非系统性检索PubMed/MEDLINE于2025年8月进行,纳入指南、综述和原始研究。完全性转移灶切除可能带来生存获益并允许残留病灶的病理与分子特征分析,但须权衡手术并发症,国际指南强调证据水平低且需谨慎选择患者。
要点
- 寡进展可能源于克隆演化动态,空间局限的亚克隆突变与微环境生态位导致治疗反应差异。
- 完全性转移灶切除可能带来生存获益,并允许对残留病灶进行病理和分子特征分析。
- 国际指南认可转移灶手术切除的作用,但强调证据水平低且需严格选择患者。
核心结论
- 来自寡转移情境的有限证据制约了寡进展性肾细胞癌的最佳患者选择与时机策略。
研究设计与样本
- 非系统性检索PubMed/MEDLINE于2025年8月进行,纳入指南、综述和原始研究,并通过手动参考文献筛选补充来源。
主要发现
- 寡进展可能源于克隆演化动态,空间局限的亚克隆突变与微环境生态位导致对治疗的不同反应。
- 完全性转移灶切除可能带来生存获益、避免系统性治疗的毒性副作用,并可能对残留病灶进行组织病理学和分子特征分析。
- 手术在延迟性减瘤性肾切除术中作为寡进展部位尤为重要,但须权衡不可忽视的手术并发症发生率。
关键数值与推荐
- 国际指南认可转移性肾细胞癌中手术切除的作用,但强调证据水平低且需仔细选择患者。
临床怎么用
- 在寡进展性肾细胞癌中,手术决策应基于谨慎的患者选择,综合考虑完全性转移灶切除的潜在生存获益与手术并发症风险。
局限性
- 证据有限且 derived from 寡转移情境,制约了最佳患者选择与时机策略的制定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. METHODS: A non-systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and original studies. Additional sources were identified through manual reference screening. RESULTS: Oligoprogression in RCC likely arises from clonal evolution dynamics, with spatially confined subclone mutations and microenvironmental niches yielding differential responses to treatment. Complete metastasectomy may offer a survival benefit, spare patients toxic side effects of systemic therapy, and offers the possibility of histopathological and molecular characterisation of residual disease. Surgery is also particularly important in delayed cytoreductive nephrectomy as the site of oligoprogression. However, this must be weighed against non-negligible surgical morbidity and complication rates. International guidelines recognise the role of surgical resection in the metastatic setting but emphasise low evidence levels and careful patient selection requirements. CONCLUSION: Limited evidence derived from the oligometastatic context constrains optimal patient selection and timing strategies in oligoprogressive RCC. Following the establishment of consensus over definitions and research gaps, future research integrating molecular biomarkers, novel imaging tracers, and multicentre collaborative studies will be essential to develop evidence-based surgical management protocols for this increasingly common clinical scenario.
引用
- Re C, Ince WHJ, Bickley L, et al. Oligoprogressive renal cell carcinoma: What is the role of surgery? BJU Int. 2026. PMID: 41969229. doi:10.1111/bju.70281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。